Document:

EX-10.2

 Exhibit 10.2 

Execution Version 

SPONSOR VESTING AGREEMENT 

This SPONSOR VESTING AGREEMENT (this “Agreement”), dated as of June 9, 2021, is made by and between Khosla Ventures SPAC Sponsor
LLC, a Delaware limited liability company (the “Sponsor”), Khosla Ventures Acquisition Co., a Delaware corporation (the “Company”), Valo Health, LLC, a Delaware limited liability company (“Valo Health Holdco”)
and Valo Health, Inc., a Delaware corporation and a direct wholly owned subsidiary of Valo Health Holdco (“Valo Health”). The Sponsor, the Company, Valo Health Holdco and Valo Health are sometimes referred to herein individually as a
“Party” and collectively as the “Parties”. 
 WHEREAS, the Sponsor holds (i) 4,760,000 shares of Acquiror Class B
Common Stock, (ii) 5,000,000 shares of Acquiror Class K Common Stock and (iii) 990,000 shares of Acquiror Class A Common Stock (the “Private Placement Shares”); 

WHEREAS, contemporaneously with the execution and delivery of this Agreement, the Company, Killington Merger Sub Inc., a Delaware corporation
and a direct wholly owned subsidiary of the Company (“Merger Sub”), Valo Health Holdco and Valo Health have entered into an Agreement and Plan of Merger (as amended or modified from time to time, the “Merger
Agreement”), dated as of the date hereof, pursuant to which, among other transactions, Valo Health Holdco would merge with and into Valo Health, and subsequently Merger Sub would merge with and into Valo Health, with Valo Health continuing
on as the surviving entity and a wholly owned subsidiary of the Company (the “Surviving Corporation”), on the terms and conditions set forth therein; 

WHEREAS, as of the Effective Time, all of the 4,760,000 shares of Acquiror Class B Common Stock held by Sponsor will be converted into an
aggregate of 5,795,999 shares of Acquiror Class A Common Stock (the “Vested Shares”) and all of the 5,000,000 shares of Acquiror Class K Common Stock held by the Sponsor will be converted into an aggregate of 8,697,479
shares of Acquiror Class A Common Stock (the “Unvested Shares,” and together with the Vested Shares, the “Sponsor Shares” and such conversion, the “Sponsor Share Conversion”); and 

WHEREAS, the Sponsor Share Conversion is intended to qualify as a “reorganization” pursuant to Section 368(a)(1)(E) of the
Internal Revenue Code of 1986, as amended (the “Code”) and this Agreement is hereby adopted as a “plan of reorganization” within the meaning of Treasury Regulations
Section 1.368-2(g). 
 NOW, THEREFORE, in consideration of the premises and the mutual promises
contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: 

1. Definitions. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Merger
Agreement. In addition to the terms defined elsewhere in this Agreement, the following terms shall have the meanings indicated when used in this Agreement with initial capital letters: 

“Board” means the Board of Directors of the Company. 

  
 1 

 “Change of Control” means (i) the sale of all or substantially all of
the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company’s outstanding voting power and outstanding stock immediately
prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such
transaction, (iii) the sale of all of the securities of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction, other than the Merger, in which the owners of the Company’s
outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the
acquisition of securities directly from the Company. 
 “Common Stock” means Acquiror Class A Common Stock. 

“First Price Vesting” shall occur if after the one year anniversary of the Closing Date and before the ten year anniversary of
the Closing Date the closing price of the Common Stock equals or exceeds $30.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any
20 Trading Days within a 30-Trading Day period. 
 “First Price Vesting Shares”
means 2,536,765 Unvested Shares (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like). 

“Forward Purchase Agreement” means the Forward Purchase Agreement, dated as of March 3, 2021, by and between the Company
and Sponsor, or any subscription agreement between the Company and Sponsor that may be entered into in connection with Sponsor’s obligations under the Forward Purchase Agreement. 

“Person” means any individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an
unincorporated organization, any other entity or a government or any department or agency thereof. 
 “Qualifying Strategic
Transaction” means any Strategic Transaction consummated after the Closing Date and before the one year anniversary of the Closing Date that results in the holders of Common Stock having the right to exchange their shares of Common Stock
for cash, securities or other property at an effective price of at least $15.00 per share of Common Stock (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the
like). 
 “Second Price Vesting” shall occur if after the one year anniversary of the Closing Date and before the ten year
anniversary of the Closing Date the closing price of the Common Stock equals or exceeds $40.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the
like) for any 20 Trading Days within a 30-Trading Day period. 
 “Second Price Vesting
Shares” means 2,875,000 Unvested Shares (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like). 

“Sponsor Shares” has the meaning set forth in the Recitals hereto. For the avoidance of doubt, Sponsor Shares shall not
include the Private Placement Shares or any shares of Common Stock issued pursuant to the Forward Purchase Agreement. 
 “Strategic
Transaction” means any Change of Control occurring after the Closing Date, other than (i) any reorganization, recapitalization or reclassification of the Common Stock in which holders of the Company’s voting power immediately
prior to such reorganization, recapitalization or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities and, directly or indirectly, are the holders of a majority of the voting
power of the surviving or resulting entity (or entities) with the authority or voting power to elect a majority of the members of the 

  
 2 

 
Board (or their equivalent if other than a company) of such entity or entities after such reorganization, recapitalization or reclassification, (ii) pursuant to a domestication or migratory
merger effected solely for the purpose of changing the jurisdiction of incorporation of the Company or (iii) any transaction or series of related transactions that would result in a majority of the Board or the board of directors of the
combined or resulting entity following the consummation of such transaction or series of related transactions being comprised of individuals who shall have not been members of the Board immediately prior to the consummation of such transaction or
series of related transactions. 
 “Third Price Vesting” shall occur if after the one year anniversary of the Closing Date
and before the ten year anniversary of the Closing Date the closing price of the Common Stock equals or exceeds $50.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations,
recapitalizations and the like) for any 20 Trading Days within a 30-Trading Day period. 

“Third Price Vesting Shares” means 3,285,714 Unvested Shares (as adjusted for share
sub-divisions, share capitalizations, reorganizations, recapitalizations and the like). 

“Trading Day” means any day on which shares of Common Stock are actually traded on the principal securities exchange or
securities market on which shares of Common Stock are then traded. 
 “Transfer” means the (i) sale of, offer to sell,
contract or agreement to sell, hypothecation or pledge of, grant of any option to purchase, distribution or otherwise disposition of or agreement to dispose of, in each case, directly or indirectly, filing (or participating in the filing of) a
registration statement with the SEC (other than the Proxy Statement/Registration Statement) or establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call equivalent position within the meaning of
Section 16 of the Exchange Act with respect to, any security, (ii) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any security, whether any such
transaction is to be settled by delivery of such securities, in cash or otherwise or (iii) public announcement of any intention to effect any transaction specified in clause (i) or (ii). 

2. Vesting. As of the Effective Time (i) the Vested Shares, the Private Placement Shares and any shares of Common Stock issued
pursuant to the Forward Purchase Agreement shall be fully vested and (ii) the Unvested Shares shall be subject to the vesting provisions set forth in this Section 2. The Sponsor agrees that it shall not Transfer any
Unvested Shares prior to the date such Sponsor Shares become vested pursuant to this Section 2. 
  

	 	(a)	 Upon Trading Triggers. 

 

	 	(i)	 The First Price Vesting Shares will vest as of the day following the First Price Vesting.

  

	 	(ii)	 The Second Price Vesting Shares will vest as of the day following the Second Price Vesting.

  

	 	(iii)	 The Third Price Vesting Shares will vest as of the day following the Third Price Vesting.

  

	 	(b)	 Upon Qualifying Strategic Transactions. The First Price Vesting Shares will vest upon the consummation
of any Qualifying Strategic Transaction. 

  
 3 

	 	(c)	 Upon Other Strategic Transactions. In the event of any Strategic Transaction occurring after the one-year anniversary of the Closing Date that results in all of the holders of Common Stock having the right to exchange their Common Stock for cash, securities or other property at an effective price of at least
$20.00 per share of Common Stock (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like), the Unvested Shares shall vest proportionately as follows:

  

	 	(i)	 if (and only if) the First Price Vesting shall not have occurred prior to or in connection with such Strategic
Transaction and such Strategic Transaction results in the holders of Common Stock having the right to exchange their shares of Common Stock for cash, securities or other property at an effective price greater than $20.00 per share of Common Stock
and less than or equal to $30.00 per share of Common Stock (each as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like), a number of First Price Vesting
Shares will vest in an amount equal to (a) the First Price Vesting Shares multiplied by (b) (i) one minus (ii) the quotient of (A) (I) $30.00 minus (II) the effective price per share of Common Stock in the
Strategic Transaction divided by (B) $10.00 (each as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like); 

 

	 	(ii)	 if (and only if) the Second Price Vesting shall not have occurred prior to or in connection with such Strategic
Transaction and such Strategic Transaction results in the holders of Common Stock having the right to exchange their shares of Common Stock for cash, securities or other property at an effective price greater than $30.00 per share of Common Stock
and less than or equal to $40.00 per share of Common Stock (each as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like), then, (i) the First Price
Vesting shall automatically be deemed satisfied (to the extent it had not already been satisfied) and (ii) a number of Second Price Vesting Shares will vest in an amount equal to (a) the Second Price Vesting Shares multiplied by
(b) (i) one minus (ii) the quotient of (A) (I) $40.00 minus the effective price per share of Common Stock in the Strategic Transaction divided by (B) $10.00 (each as adjusted for share
sub-divisions, share capitalizations, reorganizations, recapitalizations and the like); 

  

	 	(iii)	 if (and only if) the Third Price Vesting shall not have occurred prior to or in connection with such Strategic
Transaction and such Strategic Transaction results in the holders of Common Stock having the right to exchange their shares of Common Stock for cash, securities or other property at an effective price greater than $40.00 per share of Common Stock
and less than or equal to $50.00 per share of Common Stock (each as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like), then, (i) the First Price
Vesting and Second Price Vesting shall automatically be satisfied (to the extent either had not already been satisfied) and (ii) a number of Third Price Vesting Shares will vest in an amount equal to (a) the Third Price Vesting Shares
multiplied by (b) (i) one minus (ii) the quotient of (A) (I) $50.00 minus (II) the effective price per share of Common Stock in the Strategic Transaction divided by (B) $10.00 (each as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like); and 

  
 4 

	 	(iv)	 if (and only if) the Third Price Vesting shall not have occurred prior to or in connection with such Strategic
Transaction and such Strategic Transaction results in the holders of Common Stock having the right to exchange their shares of Common Stock for cash, securities or other property at an effective price greater than $50.00 per share of Common Stock
(as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like), then each of the First Price Vesting, Second Price Vesting and Third Price Vesting shall
automatically be satisfied (to the extent any had not already been satisfied). 

  

	 	(d)	 Forfeiture. Any Unvested Shares that have not vested pursuant to the foregoing provisions following any
Strategic Transaction or as of the 10th anniversary of the Closing Date shall be forfeited by the Sponsor for no consideration. 

3. Tax Treatment. Each of the Company and the Sponsor shall treat the Sponsor Share Conversion as a “reorganization” pursuant
to Section 368(a)(1)(E) of the Code and shall file their tax returns consistent with the foregoing (including attaching the statement described in Treasury Regulation Section 1.368-3(a) on or with
the U.S. federal income tax return of the Company), and none of the Parties hereto shall take any action, or fail to take any action, inconsistent with the foregoing unless otherwise required by a “determination” within the meaning of
Section 1313(a)(1) of the Code. 
 4. Termination. This Agreement shall automatically terminate, without any notice or other
action by any Party, and be void ab initio upon the termination of the Merger Agreement in accordance with its terms. Upon termination of this Agreement as provided in the immediately preceding sentence, none of the Parties shall have any
further obligations or liabilities under, or with respect to, this Agreement. 
 5. Notice. All notices and other communications
among the Parties shall be in writing and shall be deemed to have been duly given (i) when delivered in person, (ii) when delivered after posting in the United States mail having been sent registered or certified mail return receipt
requested, postage prepaid, (iii) when delivered by FedEx or other nationally recognized overnight delivery service, or (iv) when delivered by email (in each case in this clause (iv), solely if receipt is confirmed, but excluding any
automated reply, such as an out-of-office notification), addressed as follows: 

(a) If to the Sponsor prior to the Closing, or to any holder of Sponsor Shares after the Closing Date, to: 

c/o Khosla Ventures SPAC Sponsor LLC 

2128 Sand Hill Rd. 
 Menlo Park,
CA 94025 
 Attention:         Samir Kaul 

                       
  Peter Buckland 
 Email:              sk@khoslaventures.com 

                       
  pb@khoslaventures.com 
 with copies to (which shall not constitute notice): 

Latham & Watkins LLP 

505 Montgomery Street, Suite 2000 

San Francisco, CA 94111 

Attention:         Jim Morrone 

                       
  Luke J. Bergstrom 

                       
  Lauren Lefcoe 
 Email:              jim.morrone@lw.com 

                       
 luke.bergstrom@lw.com 

                       
 lauren.lefcoe@lw.com 

  
 5 

 (b) If to the Company prior to the Closing to: 

Khosla Ventures Acquisition Co. 

2128 Sand Hill Rd. 
 Menlo Park,
CA 94025 
 Attention:         Samir Kaul 

                       
  Peter Buckland 
 Email:              sk@khoslaventures.com 

                       
  pb@khoslaventures.com 
 with copies to (which shall not constitute notice): 

Latham & Watkins LLP 

505 Montgomery Street, Suite 2000 

San Francisco, CA 94111 

Attention:         Jim Morrone 

                       
  Luke J. Bergstrom 

                       
  Lauren Lefcoe 
 Email:              jim.morrone@lw.com 

                       
  luke.bergstrom@lw.com 

                       
  lauren.lefcoe@lw.com 
 (c) If to Valo Health Holdco or Valo Health prior to the Closing, or to the Company or the Surviving
Corporation after the Closing Date, to: 
 Valo Health, Inc. 

399 Boylston Street 
 Boston, MA
02116 
 Attention:         David A. Berry, MD, Ph.D 

                       
  Jeffrey Prowda 
 Email:              dberry@valohealth.com 

                       
  jprowda@valohealth.com 
 with copies to (which shall not constitute notice): 

Goodwin Procter LLP 
 100
Northern Avenue 
 Boston, MA 02210 

Attention:         Stuart M. Cable 

                       
  Joseph C. Theis 
 Email:              scable@goodwinlaw.com

                       
  jtheis@goodwinlaw.com 
 or to such other address or addresses as the Parties may from time to time designate in writing. Copies delivered solely
to outside counsel shall not constitute notice. 

  
 6 

 6. Assignment. 

(a) Neither this Agreement nor any of the rights, duties, interests or obligations of the Company or the Surviving Corporation hereunder shall
be assigned or delegated by the Company or the Surviving Corporation in whole or in part. 
 (b) This Agreement and the provisions hereof
shall inure to the benefit of, shall be enforceable by and shall be binding upon the respective assigns and successors in interest of holders of Sponsor Shares. 

7. No Third Party Beneficiaries. This Agreement shall be for the sole benefit of the Parties and their respective successors and
permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and assigns, any legal or equitable right, benefit or remedy of any nature whatsoever by reason this Agreement.
Nothing in this Agreement, expressed or implied, is intended to or shall constitute the Parties, partners or participants in a joint venture. 

8. Governing Law. This Agreement, and all claims or causes of action based upon, arising out of, or related to this Agreement or the
transactions contemplated hereby, shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without giving effect to principles or rules of conflict of Laws to the extent such principles or rules would require or
permit the application of Laws of another jurisdiction. 
 9. Headings; Counterparts. The headings in this Agreement are for
convenience only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 10. Entire Agreement. This Agreement and the agreements referenced
herein constitute the entire agreement and understanding of the Parties in respect of the subject matter hereof and supersede all prior understandings, agreements or representations by or among Parties to the extent they relate in any way to the
subject matter hereof. 
 11. Amendments. This Agreement may be amended or modified in whole or in part, only by a duly authorized
agreement in writing executed by Sponsor, the Company and (prior to the Closing Date) Valo Health. 
 12. Severability. If any
provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. The Parties further agree that if any provision contained herein is,
to any extent, held invalid or unenforceable in any respect under the Laws governing this Agreement, they shall take any actions necessary to render the remaining provisions of this Agreement valid and enforceable to the fullest extent permitted by
Law and, to the extent necessary, shall amend or otherwise modify this Agreement to replace any provision contained herein that is held invalid or unenforceable with a valid and enforceable provision giving effect to the intent of the Parties. 

13. Jurisdiction; Waiver of Jury Trial. 

(a) Any proceeding or Action based upon, arising out of or related to this Agreement or the transactions contemplated hereby must be brought in
the Court of Chancery of the State of Delaware (or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware), or, if it has or can acquire jurisdiction, in the United States District Court for
the District of Delaware, and each of the Parties irrevocably (i) submits to the exclusive jurisdiction of each such court in any such proceeding or Action, (ii) waives any objection it
may now or hereafter have to personal 

  
 7 

 
jurisdiction, venue or to convenience of forum, (iii) agrees that all claims in respect of the proceeding or Action shall be heard and determined only in any such court and (iv) agrees
not to bring any proceeding or Action arising out of or relating to this Agreement or the transactions contemplated hereby in any other court. Nothing herein contained shall be deemed to affect the right of any Party to serve process in any manner
permitted by Law or to commence Legal Proceedings or otherwise proceed against any other Party in any other jurisdiction, in each case, to enforce judgments obtained in any Action, suit or proceeding brought pursuant to this
Section 13. 
 (b) EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS
AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY, UNCONDITIONALLY AND VOLUNTARILY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN
RESPECT OF ANY ACTION, SUIT OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY. 

14. Enforcement. The Parties agree that irreparable damage could occur in the event that any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent any breach, or threatened breach, of this Agreement and to
specific enforcement of the terms and provisions of this Agreement, in addition to any other remedy to which any Party is entitled at law or in equity. In the event that any Action shall be brought in equity to enforce the provisions of this
Agreement, no Party shall allege, and each Party hereby waives the defense, that there is an adequate remedy at law, and each Party agrees to waive any requirement for the securing or posting of any bond in connection therewith. 

15. Construction. Unless the context of this Agreement otherwise requires, (i) words of any gender include each other gender;
(ii) words using the singular or plural number also include the plural or singular number, respectively; (iii) the terms “hereof,” “herein,” “hereby,” “hereto” and derivative or similar words refer
to this entire Agreement; (iv) the term “Section” refers to the specified Section of this Agreement; (v) the word “including” shall mean “including, without limitation”; (vi) the word “or” shall
be disjunctive but not exclusive; (vii) references to statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall be construed as including all statutory and regulatory provisions consolidating,
amending or replacing the statute or regulation; and (viii) whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Trading Days are specified. 

[Signature Pages Follow] 

  
 8 

 IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be duly executed
as of the day and year first above written. 
  

			
	KHOSLA VENTURES SPAC SPONSOR LLC
		
	By:	 	              

		 	Name:
		 	Title:
	
	KHOSLA VENTURES ACQUISITION CO.
		
	By:	 	              

		 	Name:
		 	Title:
	
	VALO HEALTH, LLC
		
	By:	 	              

		 	Name:
		 	Title:
	
	VALO HEALTH, INC.
		
	By:	 	              

		 	Name:
		 	Title:

 [Signature Page to Sponsor Vesting Agreement]EX-10.3

 Exhibit 10.3 

Execution Version 

SPONSOR SUPPORT AGREEMENT 

This Sponsor Support Agreement (this “Sponsor Agreement”) is dated as of June 9, 2021, by and among Khosla Ventures SPAC
Sponsor LLC, a Delaware limited liability company (the “Sponsor Holdco”), the Persons set forth on Schedule I hereto (together with the Sponsor Holdco, each, a “Sponsor” and, together, the
“Sponsors”), Khosla Ventures Acquisition Co., a Delaware corporation (“Acquiror”), Valo Health, LLC, a Delaware limited liability company (“Company Holdco”) and Valo Health, Inc., a Delaware
corporation and direct wholly owned subsidiary of Company Holdco (the “Company”). Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. 

RECITALS 
 WHEREAS, as of
the date hereof, the Sponsors collectively are the holders of record and the “beneficial owners” (within the meaning of Rule 13d-3 under the Exchange Act) of 990,000 shares of Acquiror Common
Class A Common Stock, 5,000,000 shares of Acquiror Class B Common Stock and 5,000,000 shares of Acquiror Class K Common Stock in the aggregate as set forth on Schedule I attached hereto; 

WHEREAS, contemporaneously with the execution and delivery of this Sponsor Agreement, Acquiror, Killington Merger Sub Inc., a Delaware
corporation (“Merger Sub”), Company Holdco and the Company, have entered into an Agreement and Plan of Merger (as amended or modified from time to time, the “Merger Agreement”), dated as of the date hereof, pursuant
to which, among other transactions, Merger Sub will be merged with and into the Company, with the Company continuing on as the surviving corporation and a wholly owned subsidiary of Acquiror, on the terms and conditions set forth therein; and 

WHEREAS, as an inducement to Acquiror, Company Holdco and the Company to enter into the Merger Agreement and to consummate the transactions
contemplated therein, the parties hereto desire to agree to certain matters as set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements contained herein, and intending to be legally bound hereby, the
parties hereto hereby agree as follows: 
 ARTICLE I 

SPONSOR SUPPORT AGREEMENT; COVENANTS 

Section 1.1 Binding Effect of Merger Agreement. Each Sponsor hereby acknowledges that it has read the Merger Agreement and this
Sponsor Agreement and has had the opportunity to consult with its tax and legal advisors. Each Sponsor shall be bound by and comply with Sections 7.4 (No Solicitation by Acquiror) and 11.12 (Publicity) of the Merger Agreement (and
any relevant definitions contained in any such Sections) to the same extent as such provisions apply to Acquiror as if such Sponsor was an original signatory to the Merger Agreement with respect to such provisions. 

Section 1.2 No Transfer. During the period commencing on the date hereof and ending on the earliest of (a) the Effective
Time, (b) such date and time as the Merger Agreement shall be terminated in accordance with Section 10.1 thereof (the earlier of (a) and (b), the “Expiration Time”) and (c) the liquidation of Acquiror, each
Sponsor shall not (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly 

 
or indirectly, file (or participate in the filing of) a registration statement with the SEC (other than the Proxy Statement/Registration Statement) or establish or increase a put equivalent
position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act, with respect to any shares of Acquiror Common Stock owned by such Sponsor, (ii) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any shares of Acquiror Common Stock owned by such Sponsor or (iii) take any action in furtherance of any of the matters
described in the foregoing clauses (i) and (ii). 
 Section 1.3 New Shares. In the event that (a) any shares of Acquiror
Common Stock or other equity securities of Acquiror are issued to a Sponsor after the date of this Sponsor Agreement pursuant to any stock dividend, stock split, recapitalization, reclassification, combination or exchange of shares of Acquiror
Common Stock of, on or affecting the shares of Acquiror Common Stock owned by such Sponsor or otherwise, (b) a Sponsor purchases or otherwise acquires beneficial ownership of any shares of Acquiror Common Stock or other equity securities of
Acquiror after the date of this Sponsor Agreement, or (c) a Sponsor acquires the right to vote or share in the voting of any shares of Acquiror Common Stock or other equity securities of Acquiror after the date of this Sponsor Agreement (such
shares of Acquiror Common Stock or other equity securities of Acquiror, collectively the “New Securities”), then such New Securities acquired or purchased by such Sponsor shall be subject to the terms of this Sponsor Agreement to the same
extent as if they constituted the shares of Acquiror Common Stock owned by such Sponsor as of the date hereof. 
 Section 1.4 Closing
Date Deliverables. On the Closing Date, Sponsor Holdco and the KVAC Holders (as defined therein) shall deliver to Acquiror and the Company a duly executed copy of that certain Amended and Restated Registration Rights Agreement, by and among
Acquiror, Sponsor Holdco, the KVAC Holders, and the Target Holders (as defined therein), in substantially the form attached as Exhibit C to the Merger Agreement. 

Section 1.5 Sponsor Agreements. 

(a) At any meeting of the stockholders of Acquiror, however called, or at any adjournment thereof, or in any other circumstance in which the
vote, consent or other approval of the stockholders of Acquiror is sought, each Sponsor shall (i) appear at each such meeting or otherwise cause all of its shares of Acquiror Common Stock to be counted as present thereat for purposes of
calculating a quorum and (ii) vote (or cause to be voted), or execute and deliver a written consent (or cause a written consent to be executed and delivered) covering, all of its shares of Acquiror Common Stock: 

(i) in favor of each Transaction Proposal; 

(ii) in any other circumstances upon which a consent or other approval is required under the certificate of incorporation of
Acquiror, as amended from time to time, or otherwise sought with respect to the Merger Agreement or the Transactions, to vote, consent or approve (or cause to be voted, consented or approved) all shares of Acquiror Common Stock held at such time in
favor thereof, including any Anti-Dilution Waiver; 
 (iii) against any Business Combination Proposal or any proposal
relating to a Business Combination Proposal (in each case, other than the Transaction Proposals); 

  
 2 

 (iv) against any merger agreement or merger (other than the Merger
Agreement and the Merger), consolidation, combination, sale of substantial assets, reorganization, recapitalization, dissolution, liquidation or winding up of or by Acquiror; 

(v) against any change in the business, management or Board of Directors of Acquiror (other than in connection with the
Transaction Proposals); and 
 (vi) against any and all other proposals that could reasonably be expected to
(A) delay or impair the ability of Acquiror or Merger Sub to consummate the Transactions or (B) except as contemplated by the Merger Agreement and Transaction Proposals, change in any manner the dividend policy or capitalization of,
including the voting rights of any class of capital stock of, Acquiror. 
 Each Sponsor hereby agrees that it shall not commit or agree to
take any action inconsistent with the foregoing. 
 (b) Each Sponsor shall comply with, and fully perform all of its obligations, covenants
and agreements set forth in, that certain (i) Letter Agreement, dated as of March 3, 2021, by and among the Sponsors and Acquiror (the “Voting Letter Agreement”), including the obligations of the Sponsors pursuant
to Section 1 therein to not redeem any shares of Acquiror Common Stock owned by such Sponsor in connection with the transactions contemplated by the Merger Agreement, (ii) Forward Purchase Agreement entered into as of March 3, 2021 between
Acquiror and Sponsor Holdco (the “Forward Purchase Agreement”) and (iii) the Sponsor Vesting Agreement (as defined below). Each Sponsor and Acquiror agrees not to amend, modify, waive, or terminate, or assign any of its rights,
interests or obligations under, such agreements without the prior written consent of the Company or Company Holdco. 
 (c) In connection
with the execution of this Agreement, Sponsor Holdco shall deliver to Acquiror, Company Holdco and the Company the Sponsor Vesting Agreement by and between Sponsor Holdco and Acquiror in the form attached hereto as Exhibit A. Sponsor
Holdco and Acquiror agree not to amend, modify, waive or terminate such agreements without the prior written consent of the Company or Company Holdco. 

(d) During the period commencing on the date hereof and ending on the earlier of the consummation of the Closing and the termination of the
Merger Agreement pursuant to Article X thereof, each Sponsor shall not modify or amend any Contract between or among such Sponsor, anyone related by blood, marriage or adoption to such Sponsor or any Affiliate of such Sponsor (other than
Acquiror or any of its Subsidiaries), on the one hand, and Acquiror or any of Acquiror’s Subsidiaries, on the other hand, including, for the avoidance of doubt, the Voting Letter Agreement. 

Section 1.6 Further Assurances. Each Sponsor shall execute and deliver, or cause to be delivered, such additional documents, and
take, or cause to be taken, all such further actions and do, or cause to be done, all things reasonably necessary (including under applicable Laws), in each case as reasonably mutually requested by Acquiror and the Company, to effect the
transactions contemplated by this Agreement on the terms and subject to the conditions set forth herein. 
 Section 1.7 No
Inconsistent Agreement. Each Sponsor hereby represents and covenants that such Sponsor has not entered into, and shall not enter into, any agreement that would in any material respect restrict, limit or interfere with the performance of such
Sponsor’s obligations hereunder. 

  
 3 

 Section 1.8 Lock-Up Agreement. Each
Sponsor will deliver to Acquiror, substantially simultaneously with the Effective Time, a duly executed copy of the Lock-Up Agreement, in the form attached as Exhibit B. 

Section 1.9 Waiver of Anti-Dilution Provision. Sponsor Holdco hereby (but subject to the consummation of the Merger) waives (for
itself, for its successors, heirs and assigns), to the fullest extent permitted by law and the Second Amended and Restated Certificate of Incorporation of Acquiror (as may be amended from time to time, the “Certificate of
Incorporation”), the provisions of (a) Section 4.3(b) of the Certificate of Incorporation to have the Acquiror Class B Common Stock convert to Acquiror Class A Common Stock at a ratio of greater than
1:1.217647, (b) Section 4.3(c) to have the Acquiror Class K Common Stock convert to Acquiror Class A Common Stock at a ratio of greater than 1:1.7394958 and (c) any other adjustments or
anti-dilution protections that arise in connection with the issuance of shares of Acquiror Common Stock (the “Anti-Dilution Waiver”). The waiver specified in this Section 1.9 shall be applicable only in connection with
the transactions contemplated by the Merger Agreement and this Agreement (and any shares of Acquiror Class A Common Stock or equity-linked securities issued in connection with the transactions contemplated by the Merger Agreement and this
Agreement) and shall be void and of no force and effect if the Merger Agreement shall be terminated for any reason. 
 ARTICLE II

 REPRESENTATIONS AND WARRANTIES 

Section 2.1 Representations and Warranties of the Sponsors. Each Sponsor represents and warrants as of the date hereof to
Acquiror, Company Holdco and the Company (solely with respect to itself, himself or herself and not with respect to any other Sponsor) as follows: 

(a) Organization; Due Authorization. If such Sponsor is not an individual, it is duly organized, validly existing and in good standing
under the Laws of the jurisdiction in which it is incorporated, formed, organized or constituted, and the execution, delivery and performance of this Sponsor Agreement and the consummation of the transactions contemplated hereby are within such
Sponsor’s corporate, limited liability company or organizational powers and have been duly authorized by all necessary corporate, limited liability company or organizational actions on the part of such Sponsor. If such Sponsor is an individual,
such Sponsor has full legal capacity, right and authority to execute and deliver this Sponsor Agreement and to perform his or her obligations hereunder. This Sponsor Agreement has been duly executed and delivered by such Sponsor and, assuming due
authorization, execution and delivery by the other parties to this Sponsor Agreement, this Sponsor Agreement constitutes a legally valid and binding obligation of such Sponsor, enforceable against such Sponsor in accordance with the terms hereof
(except as enforceability may be limited by bankruptcy Laws, other similar Laws affecting creditors’ rights and general principles of equity affecting the availability of specific performance and other equitable remedies). If this Sponsor
Agreement is being executed in a representative or fiduciary capacity, the Person signing this Sponsor Agreement has full power and authority to enter into this Sponsor Agreement on behalf of the applicable Sponsor. 

(b) Ownership. Such Sponsor is the record and beneficial owner (as defined in Rule 13d-3 of the
Exchange Act) of, and has good title to, all of such Sponsor’s shares of Acquiror Common Stock, and there exist no Liens or any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such
shares of Acquiror Common Stock (other than transfer restrictions under the Securities Act and, in the case of Sponsor Holdco, pursuant to that certain Sponsor Voting Agreement, dated as of March 26, 2021, by and among Sponsor Holdco and
Acquiror (the “Sponsor Voting Agreement”)) affecting any such shares of Acquiror Common Stock, other than Liens pursuant to 

  
 4 

 
(i) this Sponsor Agreement, (ii) the Acquiror Governing Documents, (iii) the Merger Agreement, (iv) the Voting Letter Agreement or (v) any
applicable securities Laws. Such Sponsor’s shares of Acquiror Common Stock are the only equity securities in Acquiror owned of record or beneficially by such Sponsor on the date of this Sponsor Agreement, and none of such Sponsor’s shares
of Acquiror Common Stock are subject to any proxy, voting trust or other agreement or arrangement with respect to the voting of such shares of Acquiror Common Stock, except as provided hereunder, under the Voting Letter Agreement and, in the case of
Sponsor Holdco, the Sponsor Voting Agreement. Other than pursuant to the Forward Purchase Agreement and for shares of Acquiror Class B Common Stock and shares of Acquiror Class K Common Stock, as applicable, such Sponsor does
not hold or own any rights to acquire (directly or indirectly) any equity securities of Acquiror or any equity securities convertible into, or which can be exchanged for, equity securities of Acquiror. 

(c) No Conflicts. The execution and delivery of this Sponsor Agreement by such Sponsor does not, and the performance by such Sponsor of
his, her or its obligations hereunder will not, (i) if such Sponsor is not an individual, conflict with or result in a violation of the organizational documents of such Sponsor or (ii) require any consent or approval that has not
been given or other action that has not been taken by any Person (including under any Contract binding upon such Sponsor or such Sponsor’s shares of Acquiror Common Stock), in each case, to the extent such consent, approval or other action
would prevent, enjoin or materially delay the performance by such Sponsor of its, his or her obligations under this Sponsor Agreement. 

(d) Litigation. There are no Actions pending against such Sponsor, or to the knowledge of such Sponsor threatened against such Sponsor,
before (or, in the case of threatened Actions, that would be before) any arbitrator or any Governmental Authority, which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by such Sponsor of its, his or her
obligations under this Sponsor Agreement. 
 (e) Brokerage Fees. Except for the deferred underwriting commissions and other fees
being held in the Trust Account and for fees payable pursuant to the letter agreement with J.P. Morgan Securities LLC dated April 25, 2021 in connection with the PIPE Investment, no broker, finder, investment banker or other Person is entitled
to any brokerage fee, finders’ fee or other commission in connection with the transactions contemplated by the Merger Agreement based upon arrangements made by such Sponsor, for which Acquiror or any of its Affiliates may become liable. 

(f) Affiliate Agreements. Except as set forth on Schedule II attached hereto, neither such Sponsor nor any anyone related by blood,
marriage or adoption to such Sponsor or, to the knowledge of such Sponsor, any Person in which such Sponsor has a direct or indirect legal, contractual or beneficial ownership of 5% or greater is party to, or has any rights with respect to or
arising from, any Contract with Acquiror or its Subsidiaries. 
 (g) Acknowledgment. Such Sponsor understands and acknowledges that
each of Acquiror, Company Holdco and the Company is entering into the Merger Agreement in reliance upon such Sponsor’s execution and delivery of this Sponsor Agreement. 

  
 5 

 ARTICLE III 

MISCELLANEOUS 

Section 3.1 Termination. This Sponsor Agreement and all of its provisions shall terminate and be of no further force or effect
upon the earliest of (a) the Expiration Time, (b) the liquidation of Acquiror and (c) the written agreement of the Sponsor, Acquiror and either Company Holdco or the Company. Upon such termination of this Sponsor
Agreement, all obligations of the parties under this Sponsor Agreement will terminate, without any liability or other obligation on the part of any party hereto to any Person in respect hereof or the transactions contemplated hereby, and no party
hereto shall have any claim against another (and no person shall have any rights against such party), whether under contract, tort or otherwise, with respect to the subject matter hereof; provided, however, that the termination of this Sponsor
Agreement shall not relieve any party hereto from liability arising in respect of any willful breach of this Sponsor Agreement prior to such termination. This ARTICLE III shall survive the termination of this Agreement. 

Section 3.2 Miscellaneous. Sections 11.7 (Governing Law), 11.13 (Severability) 11.14 (Jurisdiction;
Waiver of Jury Trial), and 11.15 (Enforcement) of the Merger Agreement are incorporated herein by reference and shall apply to this Agreement, mutatis mutandis. 

Section 3.3 Assignment. This Sponsor Agreement and all of the provisions hereof will be binding upon and inure to the benefit of
the parties hereto and their respective heirs, successors and permitted assigns. Neither this Sponsor Agreement nor any of the rights, interests or obligations hereunder will be assigned (including by operation of law) without the prior written
consent of the parties hereto. 
 Section 3.4 Amendment; Waiver. This Sponsor Agreement may not be amended, changed,
supplemented, waived or otherwise modified or terminated, except upon the execution and delivery of a written agreement executed by Acquiror, the Sponsor Holdco and either Company Holdco or the Company. 

Section 3.5 Notices. All notices and other communications among the parties hereto shall be in writing and shall be deemed to have
been duly given (a) when delivered in person, (b) when delivered after posting in the United States mail having been sent registered or certified mail return receipt requested, postage prepaid, (c) when delivered
by FedEx or other nationally recognized overnight delivery service or (d) when e-mailed during normal business hours (and otherwise as of the immediately following Business Day), addressed as follows: 

If to Acquiror: 
 Khosla
Ventures Acquisition Co. 
 2128 Sand Hill Rd. 

Menlo Park, CA 94025 
 Attention:
        Samir Kaul 

                        
 Peter Buckland 
 Email:              sk@khoslaventures.com 

                        
 pb@khoslaventures.com 
 with a copy to (which will not constitute notice): 

Latham & Watkins LLP 

505 Montgomery Street 
 Suite 2000

 San Francisco, California 94111 

Attention:         Jim Morrone 

                        
 Luke J. Bergstrom 

                        
 Lauren Lefcoe 

  
 6 

 Email:
             jim.morrone@lw.com 

                        
 luke.bergstrom@lw.com 

                        
 lauren.lefcoe@lw.com 
 If to Company Holdco or the Company: 

Valo Health, Inc. 
 399 Boylston
Street 
 Boston, MA 02116 

Attention:         David A. Berry, MD, Ph.D.; 

                        
 Jeffrey Prowda 
 Email:              dberry@valohealth.com 

                        
 jprowda@valohealth.com 
 with a copy to (which shall not constitute notice): 

Goodwin Procter LLP 
 100 Northern
Avenue 
 Boston, MA 02210 

Attention:         Stuart M. Cable 

                        
 Joseph C. Theis 
 Email:              scable@goodwinlaw.com 

                        
 jtheis@goodwinlaw.com 
 If to a Sponsor: 

To such Sponsor’s address set forth in Schedule I 

with a copy to (which will not constitute notice): 

Latham & Watkins LLP 

505 Montgomery Street 
 Suite 2000

 San Francisco, California 94111 

Attention:         Jim Morrone 

                        
 Luke J. Bergstrom 

                        
 Lauren Lefcoe 
 Email:              jim.morrone@lw.com 

                        
 luke.bergstrom@lw.com 

                        
 lauren.lefcoe@lw.com 
 Notwithstanding the foregoing, in the event notice is delivered pursuant to this Section 3.5 by a
means other than email, such party shall email such notice within one (1) Business Day of delivery of such notice by such other means. 

Section 3.6 Counterparts. This Sponsor Agreement may be executed in two or more counterparts (any of which may be delivered by
electronic transmission), each of which shall constitute an original, and all of which taken together shall constitute one and the same instrument. 

  
 7 

 Section 3.7 Entire Agreement. This Sponsor Agreement and the
agreements referenced herein constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersede all prior understandings, agreements or representations by or among the parties hereto to the
extent they relate in any way to the subject matter hereof. 
 [THE REMAINDER OF THIS PAGE IS INTENTIONALLY BLANK] 

  
 8 

 IN WITNESS WHEREOF, the Sponsors, Acquiror, Company Holdco and the Company have each caused
this Sponsor Support Agreement to be duly executed as of the date first written above. 
  

			
	SPONSORS:
	
	KHOSLA VENTURES SPAC SPONSOR LLC
		
	By:	 	  

		 	Name:
		 	Title:
	
	  

	Name: Vinod Khosla
	
	  

	Name: Samir Kaul
	
	  

	Name: Peter Buckland
	
	  

	Name: Jagdeep Singh
	
	  

	Name: Derek Anthony West
	
	  

	Name: Rajiv Shah
	
	  

	Name: Molly Coye
	
	  

	Name: Mario Schlosser
	
	  

	Name: Dmitri Shklovsky

 [Signature Page to Sponsor Support Agreement] 

 
			
	ACQUIROR:
	
	KHOSLA VENTURES ACQUISITION CO.
		
	By:	 	  

		 	Name:
		 	Title:

 [Signature Page to Sponsor Support Agreement] 

 
			
	COMPANY HOLDCO:
	
	VALO HEALTH LLC
		
	By:	 	  

		 	Name:
		 	Title:
	
	COMPANY:
	
	VALO HEALTH, INC.
		
	By:	 	  

		 	Name:
		 	Title:

 [Signature Page to Sponsor Support Agreement] 

 Schedule I 

Sponsor Acquiror Common Stock 
  

													
	 Sponsor
	  	Acquiror Class A Common Stock	 	 	Acquiror Class B Common Stock	 	 	Acquiror Class K Common Stock	 
	 Khosla Ventures SPAC Sponsor LLC

 
 c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	990,000	 	 	 	4,760,000	 	 	 	5,000,000	 
				
	 Vinod Khosla
  

c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	– 	(1)  	 	 	– 	(1) 	 	 	– 	(1) 
				
	 Samir Kaul
  

c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	– 	(1) 	 	 	– 	(1) 	 	 	– 	(1) 
				
	 Peter Buckland
  

c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	–  	 	 	 	–  	 	 	 	–  	 
				
	 Jagdeep Singh
  

c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	–  	 	 	 	40,000	 	 	 	–  	 
				
	 Derek Anthony West
  

c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	–  	 	 	 	40,000	 	 	 	–  	 

  
 [Schedule I to Sponsor
Support Agreement] 

													
	 Rajiv Shah
  

c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	–  	 	  	 	40,000	 	  	 	–  	 
				
	 Molly Coye
  

c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	–  	 	  	 	40,000	 	  	 	–  	 
				
	 Mario Schlosser
  

c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	–  	 	  	 	40,000	 	  	 	–  	 
				
	 Dmitri Shklovsky
  

c/o Khosla Ventures Acquisition Co.

2128 Sand Hill Rd.

Menlo Park, CA 94025
	  	 	–  	 	  	 	40,000	 	  	 	–  	 

 (1) Messrs. Khosla and Kaul may be deemed to beneficially own securities held by Khosla Ventures SPAC Sponsor LLC by virtue of
their shared control over Khosla Ventures SPAC Sponsor LLC. Each of Messrs. Khosla and Kaul disclaims beneficial ownership of securities held by Khosla Ventures SPAC Sponsor LLC. 

[Schedule I to Sponsor Support Agreement] 

 Schedule II 

Affiliate Agreements 
  

	1.	 Registration Rights Agreement, dated March 3, 2021, between Acquiror, Sponsor Holdco and certain other
security holders named therein. 

  

	2.	 Letter Agreement, dated March 3, 2021, between Acquiror and the Sponsors. 

 

	3.	 Sponsor Voting Agreement, dated March 26, 2021, between Acquiror and Sponsor Holdco.

  

	4.	 Private Placement Shares Purchase Agreement, dated March 3, 2021, between Acquiror and Sponsor Holdco.

  

	5.	 Forward Purchase Agreement, dated March 3, 2021, between Acquiror and Sponsor Holdco.

  

	6.	 Indemnity Agreement, dated March 3, 2021, between Acquiror and Peter Buckland. 

 

	7.	 Indemnity Agreement, dated March 3, 2021, between Acquiror and Jagdeep Singh. 

 

	8.	 Indemnity Agreement, dated March 3, 2021, between Acquiror and Derek Anthony West. 

 

	9.	 Indemnity Agreement, dated March 3, 2021, between Acquiror and Rajiv Shah. 

 

	10.	 Indemnity Agreement, dated March 3, 2021, between Acquiror and Molly Coye. 

 

	11.	 Indemnity Agreement, dated March 3, 2021, between Acquiror and Mario Schlosser. 

 

	12.	 Indemnity Agreement, dated March 3, 2021, between Acquiror and Dmitri Shklovsky. 

 

	13.	 Indemnity Agreement, dated March 3, 2021, between Acquiror and Samir Kaul. 

 

	14.	 Subscription Agreement, dated June 9, 2021, between Acquiror and an affiliate of certain of the Sponsors.

 [Schedule II to Sponsor Support Agreement] 

 Exhibit A 

Sponsor Vesting Agreement 

 Exhibit B 

Lock-Up Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]